Skip to main content

Table 1 Patient demographics of modified intent-to-treat population

From: Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial

Characteristic

Belotecan/Cisplatin (n = 71)

Etoposide/Cisplatin (n = 76)

p value

No.

%

No.

%

Ages, years

  

.565

 Median

67.0

66.5

 

 Range

29–91

46–80

 

Sex

    

.751

 Male

62

87.3

65

85.5

 

 Female

9

12.7

11

14.5

 

Body mass index, kg/m2

  

.004

 Median

23.5

22.0

 

 Range

15.1–30.4

15.0–30.8

 

Body surface area, m2

  

.055

 Median

1.71

1.65

 

 Range

1.30–1.99

1.26–2.06

 

ECOG performance status

    

.200

 0

23

32.4

20

26.3

 

 1

37

52.1

35

46.1

 

 2

11

15.5

21

27.6

 
  1. Abbreviation: ECOG Eastern cooperative oncology group